Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immunomedics Inc (IMMU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Multi-Billion Dollar Global Medical Device Industry Led by Cardiovascular Monitoring Devices

Global revenues for the medical device market are already a multi-billion dollar industry and the sector aims to continue its growth through leverage created through mergers and acquisitions, as well as...

LNB.CN : 0.600 (+3.45%)
NCI : 19.12 (-0.16%)
LXGTF : 0.4790 (+0.38%)
MDGL : 82.07 (+0.61%)
BEAT : 27.80 (-0.90%)
VTGN : 1.16 (-35.56%)
IMMU : 12.97 (+4.26%)
Today's Research Reports on Stocks to Watch: Immunomedics and Valeant Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / December 7, 2017 / Immunomedics soared yesterday after revealing positive data from a phase 2 study on its lead compound that could treat metastatic triple-negative breast...

VRX : 20.43 (+3.71%)
IMMU : 12.97 (+4.26%)
Analysis: Positioning to Benefit within Aradigm, General Motors, AT&T, Denbury Resources, Novavax, and Immunomedics -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aradigm Corporation (NASDAQ:ARDM),...

ARDM : 4.42 (+2.08%)
T : 36.71 (-0.05%)
GM : 41.70 (-0.76%)
DNR : 1.75 (+0.57%)
NVAX : 1.40 (-2.10%)
IMMU : 12.97 (+4.26%)
Featured Company News - Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of Migraine

Research Desk Line-up: Immunomedics Post Earnings Coverage

BHVN : 21.24 (+1.09%)
IMMU : 12.97 (+4.26%)
Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock

Investors in Immunomedics (IMMU) need to pay close attention to the stock based on moves in the options market lately.

IMMU : 12.97 (+4.26%)
Immunomedics (IMMU) Jumps: Stock Rises 5.4%

Immunomedics (IMMU) was a big mover last session, as the company saw its shares more than 5% on the day amid huge volumes.

MYGN : 31.56 (-6.46%)
IMMU : 12.97 (+4.26%)
Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium

Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company") today announced that two of its abstracts were posted online at www.abstracts2view.com/sabcs/ by the San Antonio Breast Cancer Symposium...

IMMU : 12.97 (+4.26%)
Today's Research Reports on Trending Tickers: Endo International and Immunomedics

NEW YORK, NY / ACCESSWIRE / November 10, 2017 / U.S. markets record rally stalled on Thursday on concerns of a delay in President Trump's proposed tax plan. The Dow Jones Industrial Average declined 0.43...

ENDP : 7.85 (+4.67%)
IMMU : 12.97 (+4.26%)
Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update

Announces Appointments of Michael Pehl as President and Chief Executive Officer and Brendan Delaney as Chief Commercial Officer

IMMU : 12.97 (+4.26%)
Immunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative Growth

Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company") today announced that its Board of Directors has voted to appoint Michael Pehl as President and Chief Executive Officer ("CEO"), effective...

IMMU : 12.97 (+4.26%)
Immunomedics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Immunomedics, Inc. (NASDAQ: IMMU) will be discussing their earnings results in their Q1 Earnings Call to be held on November 9, 2017 at 5:00 PM Eastern Time....

IMMU : 12.97 (+4.26%)
Immunomedics to Report First Quarter Fiscal 2018 Results and Host Conference Call and Webcast on November 9, 2017

Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company") today announced that it will host a conference call on Thursday, November 9, 2017 at 5:00 p.m. Eastern Time to discuss first quarter fiscal...

IMMU : 12.97 (+4.26%)
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?

Investors in Immunomedics (IMMU) need to pay close attention to the stock based on moves in the options market lately.

IMMU : 12.97 (+4.26%)
Technical Insights on Biotech Stocks -- Conatus Pharma, Immunomedics, INSYS Therapeutics, and InVivo Therapeutics

If you want a Stock Review on CNAT, IMMU, INSY, or NVIV then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Monday, benchmark US indices were in bullish...

CNAT : 4.13 (+0.73%)
NVIV : 0.97 (-1.02%)
INSY : 5.99 (-1.64%)
IMMU : 12.97 (+4.26%)
Immunomedics Announces Agreements to Exchange Approximately $80.0 Million of Its 4.75% Convertible Senior Notes Due 2020 for Common Stock

Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company") today announced that it has entered into privately negotiated exchange agreements with a limited number of holders of its 4.75% Convertible...

IMMU : 12.97 (+4.26%)
Immunomedics Partnering Deals and Alliances 2010 to 2017

The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.

IMMU : 12.97 (+4.26%)
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?

Investors in Immunomedics (IMMU) need to pay close attention to the stock based on moves in the options market lately.

IMMU : 12.97 (+4.26%)
Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer

Confirmed Objective Response Rate (ORR) of 34%, Two Confirmed Complete Responses (CRs) and Twelve Confirmed Partial Responses (PRs)

IMMU : 12.97 (+4.26%)
Immunomedics to Participate in Upcoming Investor Conferences

Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company") today announced that the Company will present an overview of its business at three upcoming investor conferences in September. A live...

WFC : 58.73 (-0.98%)
IMMU : 12.97 (+4.26%)
Immunomedics (IMMU) Catches Eye: Stock Up 5.1%

Immunomedics (IMMU) was a big mover last session, as the company saw its shares rise over 5% on the day amid huge volumes.

IMMU : 12.97 (+4.26%)
ALXN : 112.39 (-1.81%)

Van Meerten Stock Picks

5 Great Large Caps
Today I wanted to find 5 Large Caps that still had some upside potential.
ALL -0.53 , AMP -0.85 , LB +0.30 , AXP +0.17 , AKAM +0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.09%) this morning are up +0.08% and European stocks are down -0.12% . Most global stocks markets moved higher ahead of central bank meetings this week from the Fed, ECB and BOE. U.S.... Read More

Chart of the Day

Chart of the Day

Viking Therapeutics (VKTX) is the Barchart Chart of the Day.  The biopharmaceutical company has a Trend Spotter, a Weighted Alpha of 206.52+ and gained 254.95% in the last year
Read More

Brugler Ag Report

Today's Commentary

Corn futures are 1 to 2 cents lower this morning, with speculative attention drawn toward the beginning of bitcoin futures trading (+26% at one point overnight!). They saw gains of 1/4 to 1 1/4 cents on Friday, but nearby Dec was 1.38% for the week. ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.